Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 8,618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Disorder Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

NCT04079218
View directory record Official record
Conditions
HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions, Aging, Premature Aging, Atrophic Vaginitis, Dysbiosis, Vaginitis
Interventions
Estradiol Vaginal Insert
Drug
Lead sponsor
Kerry Murphy
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 28, 2026, 12:59 PM EDT
Not listed Phase 3 Interventional

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

NCT00006397
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Stavudine, Didanosine
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Fort Lauderdale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Not applicable Interventional Results available

iTransition Development

NCT04383223
View directory record Official record
Conditions
Human Immunodeficiency Virus, HIV Seropositivity
Interventions
iTransition
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

NCT00027261
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 28, 2026, 12:59 PM EDT
Terminated Phase 2 Interventional Results available

A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

NCT00824369
View directory record Official record
Conditions
HIV-1
Interventions
No drug will be administered
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Sacramento, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Not applicable Interventional

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

NCT00002041
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT01165203
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

NCT00942305
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Brincidofovir, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 28, 2026, 12:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences

NCT00675766
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage

NCT00984022
View directory record Official record
Conditions
Abscess, Cellulitis
Interventions
Type of dressing - Iodoform, Type of dressing - Aquacel
Device
Lead sponsor
Valleywise Health
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 28, 2026, 12:59 PM EDT
Completed No phase listed Observational

Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women

NCT00017797
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2006 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 3 Interventional

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

NCT00002359
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
The Immune Response Corporation
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
54
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

NCT00116662
View directory record Official record
Conditions
Warts
Interventions
Resiquimod
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
3 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Newnan, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 28, 2026, 12:59 PM EDT
Terminated Not applicable Interventional

Total Joint Arthroplasty (TJA) Weight Loss Study

NCT05156762
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Knee, Obesity, Morbid
Interventions
Bariatric surgery, Medical weight loss, Patient research surveys, Total joint arthroplasty (TJA), Usual standard of care
Procedure · Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

Treatment of Cholestatic Pruritus With Sertraline

NCT00058903
View directory record Official record
Conditions
Pruritus, Liver Cirrhosis, Biliary, Hepatitis C
Interventions
sertraline
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 28, 2026, 12:59 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

NCT01983761
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions
Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
Drug
Lead sponsor
Targazyme, Inc.
Industry
Eligibility
1 Year to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

NCT00314054
View directory record Official record
Conditions
Hepatitis C, Hepatic Insufficiency
Interventions
HCV-796
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Gainesville, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2008 · Synced Oct 28, 2026, 12:59 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement

NCT06489431
View directory record Official record
Conditions
Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation
Interventions
Chlorhexidine, Gentamicin, Rifampin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Mountain View, California • Chicago, Illinois • Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 12:59 PM EDT
Terminated Phase 3 Interventional Results available

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

NCT03887702
View directory record Official record
Conditions
Hepatitis B Infection, Malignant Solid Neoplasm
Interventions
Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
192
States / cities
Fort Smith, Arkansas • Anaheim, California • Antioch, California + 140 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

NCT03446573
View directory record Official record
Conditions
HIV Infections
Interventions
DTG + 3TC, TAF based regimen (TBR)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
54
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 1 Interventional

A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89

NCT00002141
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Burroughs Wellcome
Industry
Eligibility
13 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 12:59 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Exercise and COVID-19 Viral T-cell Immunity

NCT05019456
View directory record Official record
Conditions
COVID-19 Respiratory Infection, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 44 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 28, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01797445
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 28, 2026, 12:59 PM EDT
Completed No phase listed Observational

Safety Surveillance After Immunization With IXIARO

NCT01335412
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 28, 2026, 12:59 PM EDT